MCID: SCR001
MIFTS: 36

Secretory Meningioma

Categories: Cancer diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Secretory Meningioma

MalaCards integrated aliases for Secretory Meningioma:

Name: Secretory Meningioma 11 53 14 16 71
Meningioma 71

Classifications:



External Ids:

Disease Ontology 11 DOID:4588
MeSH 43 D008579
NCIt 49 C4718
SNOMED-CT 68 253081009
UMLS 71 C0025286 C1384406

Summaries for Secretory Meningioma

MalaCards based summary: Secretory Meningioma, also known as meningioma, is related to tuberculum sellae meningioma and signet ring cell adenocarcinoma. An important gene associated with Secretory Meningioma is KRT7 (Keratin 7), and among its related pathways/superpathways are Cytoskeletal Signaling and Validated nuclear estrogen receptor beta network. The drugs Thrombin and Tranexamic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and pituitary, and related phenotypes are Increased proliferation and neoplasm

Related Diseases for Secretory Meningioma

Diseases related to Secretory Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)
# Related Disease Score Top Affiliating Genes
1 tuberculum sellae meningioma 30.2 TRAF7 NF2
2 signet ring cell adenocarcinoma 29.4 SERPINA3 MUC1 KRT7 CEACAM5
3 meningioma, familial 28.6 VIM TRAF7 SUFU SMARCE1 SMARCB1 SERPINA3
4 parasagittal meningioma 28.6 TRAF7 SUFU SMARCE1 SMARCB1 POLR2A NF2
5 meningothelial meningioma 28.1 TRAF7 SUFU SMARCE1 SMARCB1 SERPINA3 POLR2A
6 scrotum paget's disease 10.3 MUC1 KRT7
7 gallbladder signet ring cell adenocarcinoma 10.3 MUC1 KRT7
8 mucinous tubular and spindle renal cell carcinoma 10.3 MUC1 KRT7
9 uterus perivascular epithelioid cell tumor 10.3 MUC1 KRT7
10 glandular cystitis 10.3 MUC1 KRT7
11 central nervous system fibrosarcoma 10.3 NF2 KRT7
12 solid adenocarcinoma with mucin production 10.3 MUC1 KRT7
13 medullary colon carcinoma 10.3 MUC1 KRT7
14 sella turcica neoplasm 10.3 TRAF7 NF2
15 sarcomatoid renal cell carcinoma 10.3 NF2 KRT7
16 lung meningioma 10.3 VIM NF2
17 intraneural perineurioma 10.3 TRAF7 NF2
18 petroclival meningioma 10.3 TRAF7 NF2
19 adenomyoma 10.2 MUC1 KRT7
20 cerebellopontine angle meningioma 10.2 SMARCE1 NF2
21 adenosquamous gallbladder carcinoma 10.2 SERPINA3 KRT7
22 sclerosing hemangioma 10.2 VIM MUC1
23 brain edema 10.2
24 xanthogranulomatous pyelonephritis 10.2 SERPINA3 KRT7
25 gastric squamous cell carcinoma 10.2 SERPINA3 KRT7
26 bile duct adenoma 10.2 VIM MUC1 KRT7
27 breast secretory carcinoma 10.2 SERPINA3 KRT7
28 adenofibroma 10.2 VIM MUC1 KRT7
29 bartholin's gland adenoid cystic carcinoma 10.2 SUFU KRT7
30 hemangioma 10.2 VIM MUC1 KRT7
31 sertoli-leydig cell tumor 10.2 VIM MUC1 KRT7
32 sertoli cell tumor 10.2 VIM MUC1 KRT7
33 thyroid gland hurthle cell carcinoma 10.2 SERPINA3 KRT7
34 villous adenoma 10.2 KRT7 CEACAM5
35 epulis 10.2 SERPINA3 KRT7
36 ampulla of vater adenocarcinoma 10.2 MUC1 KRT7
37 carcinosarcoma 10.2 VIM MUC1 KRT7
38 bladder adenocarcinoma 10.2 KRT7 CEACAM5
39 merkel cell carcinoma 10.2 VIM MUC1 KRT7
40 oncocytoma 10.2 VIM MUC1 KRT7
41 leukoplakia of penis 10.2 KRT7 CEACAM5
42 papillary cystadenocarcinoma 10.2 SERPINA3 KRT7
43 urethral villous adenoma 10.2 KRT7 CEACAM5
44 pancreatic serous cystadenocarcinoma 10.2 KRT7 CEACAM5
45 aggressive digital papillary adenocarcinoma 10.2 KRT7 CEACAM5
46 ureter adenocarcinoma 10.2 KRT7 CEACAM5
47 cutaneous mucoepidermoid carcinoma 10.2 KRT7 CEACAM5
48 malignant epithelial mesothelioma 10.2 KRT7 CEACAM5
49 vaginal tubulovillous adenoma 10.2 KRT7 CEACAM5
50 malignant spiradenoma 10.2 KRT7 CEACAM5

Graphical network of the top 20 diseases related to Secretory Meningioma:



Diseases related to Secretory Meningioma

Symptoms & Phenotypes for Secretory Meningioma

GenomeRNAi Phenotypes related to Secretory Meningioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Secretory Meningioma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.8 CEACAM5 KLF4 MUC1 NF2 POLR2A SMARCB1
2 digestive/alimentary MP:0005381 9.7 CEACAM5 KLF4 MUC1 NF2 POLR2A SMARCB1
3 immune system MP:0005387 9.61 CEACAM5 KLF4 NF2 POLR2A SERPINA3 SMARCB1
4 integument MP:0010771 9.17 KLF4 MUC1 NF2 POLR2A SERPINA3 SMARCB1

Drugs & Therapeutics for Secretory Meningioma

Drugs for Secretory Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic acid Approved Phase 4 1197-18-8 5526
3
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Prilocaine Approved Phase 4 721-50-6 4906
6 Fibrin Tissue Adhesive Phase 4
7 Antifibrinolytic Agents Phase 4
8 Hemostatics Phase 4
9 Coagulants Phase 4
10 Anesthetics, Local Phase 4
11 Anesthetics Phase 4
12 Vasoconstrictor Agents Phase 4
13 Epinephryl borate Phase 4
14 Bronchodilator Agents Phase 4
15 Neurotransmitter Agents Phase 4
16 Adrenergic beta-Agonists Phase 4
17 Adrenergic alpha-Agonists Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic Agents Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Respiratory System Agents Phase 4
22 Mydriatics Phase 4
23 Sympathomimetics Phase 4
24
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
25
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
26
Cisatracurium Approved, Investigational Phase 3 96946-41-7 62887
27
Magnesium sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9
28
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
31
Aminolevulinic acid Approved Phase 3 106-60-5 137
32 Hormones Phase 3
33 Hormone Antagonists Phase 3
34 glucocorticoids Phase 3
35 Contraceptives, Postcoital Phase 3
36 Contraceptives, Oral Phase 3
37 Contraceptive Agents Phase 3
38 Progestins Phase 3
39 Antihypertensive Agents Phase 3
40 Photosensitizing Agents Phase 3
41 Dermatologic Agents Phase 3
42
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
43
Aldesleukin Approved Phase 2 110942-02-4
44
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
45
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
46
Hydroxyurea Approved Phase 2 127-07-1 3657
47
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
48
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
49
Verapamil Approved Phase 2 152-11-4, 52-53-9 2520
50
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction Not yet recruiting NCT04756050 Phase 4 Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg
6 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
7 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
10 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
13 A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas Recruiting NCT05130866 Phase 2, Phase 3 REC-2282;Placebo
14 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
15 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Unknown status NCT03016091 Phase 2 Pembrolizumab
16 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
17 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
18 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
19 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
20 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
21 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
22 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
23 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
24 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
25 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
26 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Completed NCT00006119 Phase 2 hydroxyurea
27 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
28 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
29 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
30 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
31 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
32 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
33 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
34 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
35 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
36 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
37 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
38 A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma Recruiting NCT02847559 Phase 2
39 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
40 A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma Recruiting NCT04659811 Phase 2 Pembrolizumab
41 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
42 Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations Recruiting NCT02523014 Phase 2 Vismodegib;FAK Inhibitor GSK2256098;Capivasertib;Abemaciclib
43 SSTR2-Targeted PET Imaging of Meningioma: Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC Recruiting NCT04298541 Phase 2 Ga-68- DOTATATE;Ga-68-DOTATOC
44 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
45 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
46 An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma Recruiting NCT05023018 Phase 2 NEO100
47 A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma Recruiting NCT05425004 Phase 2 Cabozantinib
48 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib;Neratinib
49 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
50 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab

Search NIH Clinical Center for Secretory Meningioma

Genetic Tests for Secretory Meningioma

Anatomical Context for Secretory Meningioma

Organs/tissues related to Secretory Meningioma:

MalaCards : Brain, Spinal Cord, Pituitary, Bone, Lung

Publications for Secretory Meningioma

Articles related to Secretory Meningioma:

(show top 50) (show all 64)
# Title Authors PMID Year
1
[A rare case of tumor-to-tumor metastasis: secondary deposits of pulmonary adenocarcinoma in a secretory meningioma]. 53 62
12368922 2002
2
Pseudopsammomatous meningioma with elevated serum carcinoembryonic antigen: a true secretory meningioma. Case report. 53 62
1984492 1991
3
Radiographic Differentiation of Secretory Meningiomas and WHO Grade 2 Meningiomas: When Atypical Features Are Not Always Predictive of Atypical Tumors. 62
35724883 2022
4
[Application of specific staining in the diagnosis of secretory meningioma]. 62
35359049 2022
5
Reactive hyperplasia of vascular pericytes in meningioma: immunohistochemical and ultrastructural studies of two cases. 62
36106072 2022
6
Extremely intricate labyrinthine structures: an electron microscopic observation of peculiar invaginations of the plasma membrane found in secretory meningioma. 62
36106074 2022
7
A rare case of meningioma recurrence on a titanium mesh cranioplasty. 62
34726561 2021
8
Peritumoral Brain Edema and Surgical Outcome in Secretory Meningiomas: A Matched-Cohort Analysis. 62
33022430 2021
9
Secretory meningioma with bone infiltration and orbital spreading. 62
30957470 2019
10
Epithelial differentiation with microlumen formation in meningioma: diagnostic utility of NHERF1/EBP50 immunohistochemistry. 62
29983887 2018
11
Pearls & Oy-sters: Persistent elevation of serum carcinoembryonic antigen in secretory meningioma. 62
29438031 2018
12
Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients. 62
29143274 2018
13
KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas. 62
28651379 2017
14
Genetic landscape of meningioma. 62
27624470 2016
15
Secretory Meningiomas: Increased Prevalence of Seizures Secondary to Edema Formation in a Rare Histologic Subtype. 62
27241088 2016
16
The Possible Role of Mast Cells and VEGF in Peritumoural Oedema of Secretory Meningioma. 62
29901331 2016
17
A solitary fibrous tumor with concurrent meningioma at the same site: A case report and review of the literature. 62
27284369 2016
18
Secretory meningioma with KLF4 K409Q mutation in collision with glioma. 62
26227255 2015
19
Crush Cytology of Secretory Meningioma: A Case Report. 62
26605274 2015
20
A Left Frontal Secretory Meningioma Can Mimic Transformed Migraine With and Without Aura. 62
26084240 2015
21
Malignant meningioma with adenocarcinoma-like metaplasia: demonstration of intestinal phenotype. 62
25377638 2015
22
Secretory meningioma: a diagnostic pitfall. 62
24943746 2014
23
Secretory meningiomas: immunohistochemical pattern of lectin and ultrastructure of pseudopsammoma bodies. 62
25118899 2014
24
Unusual features in four canine meningiomas. 62
23660088 2013
25
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. 62
23404370 2013
26
Differential expression of extracellular matrix-related genes in rare variants of meningioma. 62
22995327 2013
27
Skull base secretory meningioma. Value of histological and immunohistochemical findings for peritumoral brain edema formation. 62
23645307 2013
28
Secretory meningiomas: clinical, radiological and pathological findings in 70 consecutive cases at one institution. 62
23412548 2013
29
Determination of grade and subtype of meningiomas by using histogram analysis of diffusion-tensor imaging metrics. 62
22084207 2012
30
Malignant meningiomas with epithelial (adenocarcinoma-like) metaplasia: a study of 3 cases. 62
21558975 2011
31
Secretory meningiomas: a benign subgroup causing life-threatening complications. 62
19066343 2009
32
Secretory meningiomas of the orbit. 62
19929671 2009
33
Primary temporal bone secretory meningioma presenting as chronic otitis media. 62
18172659 2008
34
Secretory meningioma of the middle ear: a light microscopic, immunohistochemical and ultrastructural study of one case. 62
18181836 2008
35
Secretory Meningioma Mimicking Malignancy. 62
27408092 2008
36
Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study. 62
17721284 2007
37
A rare case of recurrent secretory meningioma with malignant transformation. 62
16954080 2006
38
[Analysis of clinical and pathological features of secretory meningiomas]. 62
16761441 2006
39
Anaplastic secretory meningioma: a case report. 62
16929789 2006
40
Temporal bone secretory meningioma presenting as a middle ear mass. 62
16517091 2006
41
Secretory meningioma: immunohistochemical findings and evaluation of mast cell infiltration. 62
16010579 2006
42
Meningioma with the unique coexistence of secretory and lipomatous components: a case report with immunohistochemical and ultrastructural study. 62
16320819 2005
43
Metastasis of pulmonary adenocarcinoma in right sylvian secretory meningioma. 62
11926470 2002
44
Secretory meningioma: clinicopathologic features of eight cases. 62
11437574 2001
45
Secretory meningiomas: clinical and immunohistochemical observations. 53
11220371 2001
46
Secretory meningioma, a rare meningioma subtype with characteristic glandular differentation: an histological and immunohistochemical study of 9 cases. 62
10655573 1999
47
Cytologic features of secretory meningioma. 62
10097697 1999
48
Secretory meningioma with lipomatous component: case report. 62
10746964 1999
49
Secretory meningioma of the brain. Report of two cases. 62
10464426 1999
50
Lipomatous secretory meningioma: case report and review of the literature. 62
9833895 1998

Variations for Secretory Meningioma

Expression for Secretory Meningioma

Search GEO for disease gene expression data for Secretory Meningioma.

Pathways for Secretory Meningioma

Pathways related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.41 VIM NF2 MUC1 KRT7
2 10.13 SMARCE1 SMARCB1

GO Terms for Secretory Meningioma

Cellular components related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RSC-type complex GO:0016586 9.56 SMARCE1 SMARCB1
2 npBAF complex GO:0071564 9.46 SMARCE1 SMARCB1
3 brahma complex GO:0035060 9.26 SMARCE1 SMARCB1
4 bBAF complex GO:0140092 8.92 SMARCE1 SMARCB1

Biological processes related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell differentiation GO:0045597 9.43 SMARCE1 SMARCB1 NF2
2 positive regulation of histone H4 acetylation GO:0090240 8.92 SMARCB1 MUC1

Sources for Secretory Meningioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....